TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 37988294

Group type: EXPERIMENTAL
Intervention: Stereotactic arrhythmia radioablation (STAR) with a total dose of 25 Gy (single fraction) delivered in 3 min
Number of subjects: 20
Study: 37988391

Group type: EXPERIMENTAL
Intervention: Rifampicin
Number of subjects: 387

Group type: EXPERIMENTAL
Intervention: Isoniazid
Number of subjects: 387

Group type: EXPERIMENTAL
Intervention: Pyrazinamide
Number of subjects: 387
Study: 37988402

Group type: EXPERIMENTAL
Intervention: Daily intra-muscular paromomycin (20mg/kg, 14 days) plus oral miltefosine (allometric dose, 42 days) - PM/MF
Number of subjects: 110

Group type: COMPARATOR
Intervention: Liposomal amphotericin B (total dose of 20mg/kg, administered in four injections in week one) and oral miltefosine (allometric dose, 28 days) - LAmB/MF
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: PM/MF
Number of subjects: 110

Group type: COMPARATOR
Intervention: LAmB/MF
Number of subjects: 110
Study: 37988413

Group type: EXPERIMENTAL
Intervention: PIVKA-II ≤ 240 mAU/ml
Number of subjects: 522

Group type: COMPARATOR
Intervention: PIVKA-II > 240 mAU/ml
Number of subjects: 522

Group type: EXPERIMENTAL
Intervention: Incorporating PIVKA-II into Hangzhou criteria
Number of subjects: 522
Study: 37988439

Group type: EXPERIMENTAL
Intervention: Sapien-3 outflow at Evolut node 4
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: Sapien-3 outflow at Evolut node 5
Number of subjects: 219
Study: 37988449

Group type: EXPERIMENTAL
Intervention: Higher baseline remnant cholesterol (RC) levels (per SD in log-transformed)
Number of subjects: 3321

Group type: EXPERIMENTAL
Intervention: Long-term trajectories of RC levels during young adulthood
Number of subjects: 3321
Study: 37988638

Group type: EXPERIMENTAL
Intervention: Induction pembrolizumab (200 mg, once every 21 days) followed by risk-adapted thoracic radiotherapy (55 Gy for tumors or lymph nodes >20 cc, 48 Gy for smaller lesions) and consolidation pembrolizumab for 1 year.
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Induction pembrolizumab (200 mg, once every 21 days)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Risk-adapted thoracic radiotherapy
Number of subjects: 25
Study: 37988648

Group type: EXPERIMENTAL
Intervention: Disitamab vedotin (DV) 2 mg/kg IV infusion, once every 2 weeks
Number of subjects: 107
Study: 37988814

Group type: EXPERIMENTAL
Intervention: SpHb-guided management
Number of subjects: 130

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 130
Study: 37988846

Group type: EXPERIMENTAL
Intervention: Composite Pulmonary Embolism Shock (CPES) score > 3
Number of subjects: 848

Group type: EXPERIMENTAL
Intervention: CPES score > 4
Number of subjects: 848

Group type: EXPERIMENTAL
Intervention: Computed tomographic RV enlargement instead of echocardiographic RV dysfunction
Number of subjects: 848

Group type: EXPERIMENTAL
Intervention: Subgroup analysis of intermediate-risk PE
Number of subjects: 848
Study: 37989134

Group type: EXPERIMENTAL
Intervention: Latin dance intervention
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Moderate- to vigorous-intensity physical activity
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Moderate- to vigorous-intensity physical activity and total physical activity
Number of subjects: 330
Study: 37989142

Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol (25 micrograms every 3 hours for up to five doses)
Number of subjects: 2546

Group type: COMPARATOR
Intervention: Oral misoprostol (100 micrograms every 4 hours for up to two doses)
Number of subjects: 2546

Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol
Number of subjects: 2546

Group type: COMPARATOR
Intervention: Oral misoprostol
Number of subjects: 2546
Study: 37989361

Group type: EXPERIMENTAL
Intervention: mHealth intervention alone
Number of subjects: 294

Group type: EXPERIMENTAL
Intervention: mHealth intervention integrated with personal medical nutrition therapy
Number of subjects: 294

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 294
Study: 37989362

Group type: EXPERIMENTAL
Intervention: Real-time electronic heart team decision-making approach
Number of subjects: 490

Group type: COMPARATOR
Intervention: Conventional heart team approach
Number of subjects: 490
Study: 37989369

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: Hyperandrogenism
Number of subjects: 264

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 264
Study: 37989370

Group type: EXPERIMENTAL
Intervention: Cervical softening measured with the Pregnolia System
Number of subjects: 390

Group type: COMPARATOR
Intervention: Cervical length measurement and fetal fibronectin test (not specified if used in combination)
Number of subjects: 390
Study: 37989376

Group type: EXPERIMENTAL
Intervention: Community Paramedicine at Clinic (CP@clinic) programme
Number of subjects: 41
Study: 37989381

Group type: EXPERIMENTAL
Intervention: Single-antiplatelet therapy (SAPT) with aspirin 75-100 mg for 6 months
Number of subjects: 650

Group type: COMPARATOR
Intervention: Oral anticoagulant (OAC) with warfarin, therapeutic international normalised ratio at 1.8-2.5 for 6 months
Number of subjects: 650
Study: 37989482

Group type: EXPERIMENTAL
Intervention: Ombrabulin (35 mg/m²) in combination with paclitaxel and carboplatin
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Ombrabulin (25 mg/m² or 30 mg/m²) in combination with paclitaxel and carboplatin
Number of subjects: 18
Study: 37989586

Group type: EXPERIMENTAL
Intervention: Nicotine Corrective Messaging (NCM)
Number of subjects: 794

Group type: COMPARATOR
Intervention: No message control
Number of subjects: 794
Study: 37989710

Group type: EXPERIMENTAL
Intervention: ADHD
Number of subjects: 89

Group type: COMPARATOR
Intervention: WMH (white matter hyperintensity)
Number of subjects: 89
Study: 37989943

Group type: EXPERIMENTAL
Intervention: 5% albumin
Number of subjects: 104

Group type: COMPARATOR
Intervention: Balanced crystalloid solution (Plasma-Lyte)
Number of subjects: 104
Study: 37990160

Group type: EXPERIMENTAL
Intervention: BCI-assisted hand motor imagery (MI) training
Number of subjects: 30

Group type: COMPARATOR
Intervention: Hand motor imagery (MI) training not supported by BCI
Number of subjects: 30
Study: 37990162

Group type: EXPERIMENTAL
Intervention: isatuximab-RVd
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: elotuzumab-RVd
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: RVd (6 cycles of 21 days)
Number of subjects: 179

Group type: COMPARATOR
Intervention: RVd (general)
Number of subjects: 179
Study: 37990163

Group type: EXPERIMENTAL
Intervention: Tonic motor activation (TOMAC) sessions for 30 minutes bilaterally over the peroneal nerve when RLS symptoms presented.
Number of subjects: 20
Study: 37990173

Group type: COMPARATOR
Intervention: Light hypnosis (non-drug intervention) in healthy controls (CTRL)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: EEG microstate anomalies
Number of subjects: 126
Study: 37990202

Group type: EXPERIMENTAL
Intervention: Genotyping through saliva samples submitted by participants with ARFID
Number of subjects: 3000

Group type: EXPERIMENTAL
Intervention: Comprehensive online consent and phenotyping
Number of subjects: 3000
Study: 37990223

Group type: EXPERIMENTAL
Intervention: NLR cut-off ≥ 7.95
Number of subjects: 5034
Study: 37990224

Group type: EXPERIMENTAL
Intervention: Intra-mucosal injection of vitamin C (L-Ascorbic acid 1000 mg/5 ml)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Diode laser (980 nm, 1.5 W, continuous wave mode)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 26
Study: 37990250

Group type: EXPERIMENTAL
Intervention: eHealth behaviour change support (BCS) program
Number of subjects: 78
Study: 37990252

Group type: EXPERIMENTAL
Intervention: 120 minutes of class-scheduled physical activity and physical education per week for 9 months (Intervention schools n=19)
Number of subjects: 1370

Group type: COMPARATOR
Intervention: Normal 2 hours of weekly physical education (Control schools n=9)
Number of subjects: 1370
Study: 37990322

Group type: EXPERIMENTAL
Intervention: Cough and Sputum Assessment Questionnaire (CASA-Q)
Number of subjects: 48
Study: 37990323

Group type: EXPERIMENTAL
Intervention: PROMIS SD-SF-8b
Number of subjects: 1022
Study: 37990345

Group type: EXPERIMENTAL
Intervention: Implementation facilitation (IF) for IPV screening programs over 6 months with external and internal facilitators.
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Qualitative data collection using the i-PARIHS framework through interviews with key informants.
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Quantitative data on IPV screening uptake from medical records and surveys.
Number of subjects: 8
Study: 37990359

Group type: EXPERIMENTAL
Intervention: Kidneys from donors with acute kidney injury (AKI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Kidneys from non-AKI donors
Number of subjects: 0
Study: 37990636

Group type: EXPERIMENTAL
Intervention: Engineered tones linked to brainwaves (LB)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Random engineered tones not linked to brainwaves (NL, sham control)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Both LB and NL groups
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: LB and NL groups
Number of subjects: 106
Study: 37990670

Group type: EXPERIMENTAL
Intervention: High Protein (HP) diet (30% protein, 30% fat, 40% carbohydrate)
Number of subjects: 12

Group type: COMPARATOR
Intervention: High Carbohydrate (HC) diet (15% protein, 30% fat, 55% carbohydrate)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: High Protein (HP) diet
Number of subjects: 12
Study: 37990929

Group type: EXPERIMENTAL
Intervention: Regional citrate anticoagulation
Number of subjects: 89

Group type: COMPARATOR
Intervention: No anticoagulation
Number of subjects: 89
Study: 37991022

Group type: EXPERIMENTAL
Intervention: Dulaglutide
Number of subjects: 151

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 151
Study: 37991122

Group type: EXPERIMENTAL
Intervention: EQ-5D-3L questionnaire at 12 months after hospitalization for COVID-19
Number of subjects: 611

Group type: EXPERIMENTAL
Intervention: EQ-5D-3L questionnaire at 3, 6, and 9 months after hospitalization for COVID-19
Number of subjects: 611

Group type: EXPERIMENTAL
Intervention: Return to work or education
Number of subjects: 611

Group type: EXPERIMENTAL
Intervention: Persistent symptoms
Number of subjects: 611

Group type: EXPERIMENTAL
Intervention: New disabilities in instrumental activities of daily living
Number of subjects: 611

Group type: EXPERIMENTAL
Intervention: Cognitive impairment
Number of subjects: 611

Group type: EXPERIMENTAL
Intervention: Anxiety
Number of subjects: 611

Group type: EXPERIMENTAL
Intervention: Depression
Number of subjects: 611

Group type: EXPERIMENTAL
Intervention: Post-traumatic stress symptoms
Number of subjects: 611

Group type: EXPERIMENTAL
Intervention: Major cardiovascular events
Number of subjects: 611

Group type: EXPERIMENTAL
Intervention: Rehospitalization
Number of subjects: 611

Group type: EXPERIMENTAL
Intervention: All-cause mortality
Number of subjects: 611
Study: 37991178

Group type: EXPERIMENTAL
Intervention: Sacral Neuromodulation (SNM)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Personalized Conservative Treatment (PCT)
Number of subjects: 67
Study: 37991265

Group type: EXPERIMENTAL
Intervention: Quality of Life with a Ventricular Assist Device questionnaire
Number of subjects: 393
Study: 37991508

Group type: EXPERIMENTAL
Intervention: Cardiac computed tomography (CT)
Number of subjects: 3445

Group type: COMPARATOR
Intervention: Invasive coronary angiography (ICA)
Number of subjects: 3445
Study: 37991639

Group type: EXPERIMENTAL
Intervention: ABY-025 (Affibody molecule)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Automated cGMP-compliant radiosynthesis method
Number of subjects: 0
Study: 37991657

Group type: EXPERIMENTAL
Intervention: Medication optimization intervention
Number of subjects: 285

Group type: EXPERIMENTAL
Intervention: Medication optimization intervention (non-long stayers)
Number of subjects: 285

Group type: EXPERIMENTAL
Intervention: Medication optimization intervention (long stayers)
Number of subjects: 285

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 285
Study: 37991693

Group type: EXPERIMENTAL
Intervention: CT-P43
Number of subjects: 509

Group type: COMPARATOR
Intervention: Originator ustekinumab
Number of subjects: 509

Group type: EXPERIMENTAL
Intervention: CT-P43 and Originator ustekinumab
Number of subjects: 509
Study: 37991697

Group type: EXPERIMENTAL
Intervention: Baricitinib 4 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Baricitinib 2 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 37991745

Group type: EXPERIMENTAL
Intervention: Abbreviated DAPT (immediate DAPT discontinuation, followed by single APT for ≥6 months)
Number of subjects: 4579

Group type: COMPARATOR
Intervention: Standard DAPT (DAPT for ≥2 additional months, followed by single APT for 11 months)
Number of subjects: 4579

Group type: EXPERIMENTAL
Intervention: Abbreviated DAPT
Number of subjects: 4579
Study: 37991761

Group type: EXPERIMENTAL
Intervention: PRISM-guided approach (group 1)
Number of subjects: 170

Group type: COMPARATOR
Intervention: Conventional approach (group 2)
Number of subjects: 170
Study: 37991778

Group type: EXPERIMENTAL
Intervention: Neoadjuvant carboplatin (AUC 6) and docetaxel (75 mg/m2) plus pembrolizumab (200 mg) every 21 days for 6 cycles
Number of subjects: 115
Study: 37991835

Group type: EXPERIMENTAL
Intervention: CO monitoring for guidance of intraoperative fluid therapy and low-dose dobutamine infusion (2.5 μg/kg/hr) for up to 4 hours postoperatively.
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: CO-directed fluid therapy with low-dose dobutamine infusion.
Number of subjects: 34

Group type: COMPARATOR
Intervention: Standard of care (current practice without CO monitoring and dobutamine infusion).
Number of subjects: 34
Study: 37991839

Group type: EXPERIMENTAL
Intervention: Spark (v1.0), a 5-week, self-guided, CBT-based digital program using a mobile app and VR experiences
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Spark program
Number of subjects: 30
Study: 37991939

Group type: EXPERIMENTAL
Intervention: Anastrozole (6 vs 3 years after 2 to 3 years of adjuvant tamoxifen)
Number of subjects: 1781

Group type: EXPERIMENTAL
Intervention: Anastrozole (extended)
Number of subjects: 1781
Study: 37992000

Group type: EXPERIMENTAL
Intervention: Coadministration of RSVpreF and SIIV
Number of subjects: 1403

Group type: COMPARATOR
Intervention: SIIV administered alone
Number of subjects: 1403

Group type: COMPARATOR
Intervention: RSVpreF administered alone
Number of subjects: 1403
Study: 37992028

Group type: EXPERIMENTAL
Intervention: Basic physical training (BPT)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: BPT combined with functional exercises (BPTFE)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Sedentary group (Control)
Number of subjects: 24
Study: 37992063

Group type: EXPERIMENTAL
Intervention: Coded card containing treatment details
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Alternative drug packaging to conceal drug identity
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Longer refills to cover travel periods
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Health delivery improvements
Number of subjects: 20
Study: 37992138

Group type: EXPERIMENTAL
Intervention: Piezosurgery
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional rotary surgery
Number of subjects: 20
Study: 37992183

Group type: EXPERIMENTAL
Intervention: Novavax protein-based COVID-19 vaccine (NVX-CoV2373)
Number of subjects: 0

Group type: COMPARATOR
Intervention: mRNA-based boosters (BNT162b2 and mRNA-1273)
Number of subjects: 0
Study: 37992203

Group type: EXPERIMENTAL
Intervention: Immediate treatment initiation
Number of subjects: 200

Group type: COMPARATOR
Intervention: Standard of care referral to outpatient care
Number of subjects: 200
Study: 37992261

Group type: EXPERIMENTAL
Intervention: R-maintenance (Rituximab maintenance)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Interferon-alpha maintenance
Number of subjects: 0

Group type: COMPARATOR
Intervention: R-FC (Rituximab, fludarabine, cyclophosphamide)
Number of subjects: 0

Group type: COMPARATOR
Intervention: R-CHOP (Rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MRD monitoring by qPCR
Number of subjects: 0
Study: 37992970

Group type: EXPERIMENTAL
Intervention: Protein intake of 1.0 g⋅kg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Protein intakes ranging from 0.6 to 1.5 g⋅kg
Number of subjects: 16
Study: 37993030

Group type: EXPERIMENTAL
Intervention: Wearable, app-controlled, transcutaneous electrical nerve stimulation (TENS) device
Number of subjects: 142
Study: 37993033

Group type: EXPERIMENTAL
Intervention: Mirikizumab 1000 mg at week 12
Number of subjects: 170

Group type: COMPARATOR
Intervention: Placebo at week 12
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Mirikizumab (any dose) at 1 year
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Mirikizumab (any dose) at 1 year based on week 12 response
Number of subjects: 170
Study: 37993058

Group type: EXPERIMENTAL
Intervention: Online training module (OPTIC-IBD) including 24 educational videos on IBD colonic lesions, with a final assessment after 60 days.
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Online training module (OPTIC-IBD)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Control group (no additional training)
Number of subjects: 117
Study: 37993062

Group type: EXPERIMENTAL
Intervention: Endocuff Vision-assisted colonoscopy (EVC)
Number of subjects: 717

Group type: COMPARATOR
Intervention: Conventional colonoscopy (CC)
Number of subjects: 717

Group type: COMPARATOR
Intervention: 2 × CC
Number of subjects: 717

Group type: EXPERIMENTAL
Intervention: 2 × EVC
Number of subjects: 717
Study: 37993149

Group type: EXPERIMENTAL
Intervention: Niraparib (200 or 300 mg daily in a 3-weekly cycle)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Active symptom control (ASC)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Niraparib
Number of subjects: 84
Study: 37993156

Group type: EXPERIMENTAL
Intervention: Intramedullary nailing guided by the CARV protocol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Current clinical practice (control group)
Number of subjects: 0
Study: 37993168

Group type: EXPERIMENTAL
Intervention: Robotic device (ALBA) with regular treatment
Number of subjects: 32

Group type: COMPARATOR
Intervention: Regular rehabilitation only
Number of subjects: 32
Study: 37993169

Group type: EXPERIMENTAL
Intervention: AI-powered tool using wearable sensors for pain assessment
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Physiotherapy treatment
Number of subjects: 15
Study: 37993199

Group type: EXPERIMENTAL
Intervention: 3DVUS imaging assessments of peripheral arteries
Number of subjects: 3471

Group type: EXPERIMENTAL
Intervention: Higher low-density lipoprotein cholesterol (LDL-C) and elevated systolic blood pressure (SBP)
Number of subjects: 3471
Study: 37993201

Group type: EXPERIMENTAL
Intervention: Semaglutide 2.4 mg
Number of subjects: 529
Study: 37993203

Group type: EXPERIMENTAL
Intervention: Machine Learning algorithms (Lasso regression, gradient boosting)
Number of subjects: 1800

Group type: EXPERIMENTAL
Intervention: Machine Learning models
Number of subjects: 1800

Group type: EXPERIMENTAL
Intervention: Machine Learning-based approach
Number of subjects: 1800
Study: 37993279

Group type: EXPERIMENTAL
Intervention: High-intensity non-invasive ventilation (HI-NIV) during exercise training (ET)
Number of subjects: 26

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 26
Study: 37993355

Group type: EXPERIMENTAL
Intervention: Ebola vaccine trial
Number of subjects: 699
Study: 37993525

Group type: EXPERIMENTAL
Intervention: Remimazolam
Number of subjects: 79

Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 79
Study: 37993549

Group type: EXPERIMENTAL
Intervention: Customized virtual reality naturalistic scenarios
Number of subjects: 23
Study: 37993560

Group type: EXPERIMENTAL
Intervention: PIPAC-OX
Number of subjects: 342

Group type: COMPARATOR
Intervention: Primary tumor surgery
Number of subjects: 342
Study: 37993666

Group type: EXPERIMENTAL
Intervention: Hybrid telerehabilitation group (Pilates-based exercises with synchronous sessions)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Home-based group (same exercises done at home)
Number of subjects: 32
Study: 37993676

Group type: EXPERIMENTAL
Intervention: VR-Cup
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: VR-Stem
Number of subjects: 101

Group type: COMPARATOR
Intervention: Control-Cup
Number of subjects: 101

Group type: COMPARATOR
Intervention: Control-Stem
Number of subjects: 101
Study: 37993786

Group type: EXPERIMENTAL
Intervention: Transcutaneous tibial nerve stimulation (TTNS)
Number of subjects: 406

Group type: COMPARATOR
Intervention: Sham (inactive) electrical stimulation
Number of subjects: 406

Group type: EXPERIMENTAL
Intervention: TTNS
Number of subjects: 406

Group type: COMPARATOR
Intervention: Sham
Number of subjects: 406
Study: 37993831

Group type: EXPERIMENTAL
Intervention: Herbicide exposure (measured through biomarkers of herbicide concentration)
Number of subjects: 2000
Study: 37993837

Group type: EXPERIMENTAL
Intervention: Alberta Infant Motor Scale (AIMS)
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Peabody Developmental Motor Scales-2 (PDMS-2)
Number of subjects: 139
Study: 37993844

Group type: EXPERIMENTAL
Intervention: Pharmacopuncture
Number of subjects: 101

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 101
Study: 37993889

Group type: EXPERIMENTAL
Intervention: 125 mg levetiracetam twice daily for 14 days
Number of subjects: 84

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study: 37993961

Group type: EXPERIMENTAL
Intervention: TASK intervention
Number of subjects: 20
Study: 37993963

Group type: EXPERIMENTAL
Intervention: Direct emmetropia with focus-out glasses (DEFOG)
Number of subjects: 160

Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 160
Study: 37993984

Group type: EXPERIMENTAL
Intervention: e-CBT program for 9 weeks
Number of subjects: 59
Study: 37994400

Group type: EXPERIMENTAL
Intervention: bococizumab
Number of subjects: 3499
Study: 37994538

Group type: EXPERIMENTAL
Intervention: ABHR applied directly to gloved hands
Number of subjects: 641

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 641

Group type: COMPARATOR
Intervention: Gold standard
Number of subjects: 641
Study: 37994553

Group type: EXPERIMENTAL
Intervention: Prasugrel (3.75 mg/day) monotherapy
Number of subjects: 6002

Group type: COMPARATOR
Intervention: DAPT with aspirin (81-100 mg/day) and prasugrel (3.75 mg/day)
Number of subjects: 6002
Study: 37994646

Group type: EXPERIMENTAL
Intervention: Uterus transplantation (UTx)
Number of subjects: 20